左西孟旦联合左卡尼汀治疗顽固性心力衰竭患者的效果观察

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Levosimendan combined with Levocarnitine in the treatment of patients with refractory heart failure.Methods From March 2016 to July 2017,60 patients with refractory heart failure treated in our hospital were enrolled as observation subjects.They were randomly divided into observation group and control group by a random number table method,30 cases in each group.The two groups were provided with routine therapeutic measures such as ECG monitoring,oxygen therapy,diuretic,and angiotensin converting enzyme inhibitor and so forth.In the control group,only Levocarnitine used,while in the observation group,Levosimendan was added on the basis of the control group.The clinical efficacy was observed.Differences of the indicators of left ventricular end diastolic diameter(LVEDd),left ventricular end systolic diameter(LVESd),left ventricular ejection fraction(LVEF)and heart index(CI)by echocardiography (ECG)were observed.The incidence of adverse reactions between the two groups was recorded.ResultsThe total therapeutic effectiveness rate in the observation group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).Before treatment,the LVEDd,LVESd,LVEF and CI of the two groups were compared,and the differences were statistically significan (P＞0.05).After therapy,the values of LVEDd and LVESd in the observation group was significantly higher than those in the control group,and the differences were statistically significan (P＜0.05).The LVEF and CI were greatly lower than those in the control group,and the differences were statistically significan (P＜0.05).The incidence of adverse reactions was 3.33%in the observation group,while the incidence of adverse reactions in the control group was 10.0%,and the incidence of adverse reactions was compared,and the difference was statistically significan (P＞0.05).Conclusion Levosimendan combined with Levocarnitine in the treatment of refractory heart failure can obtain a favorable clinical effect by effectively improving the patients′cardiac function in high safety,which is worthy of promotion in clinical practice.

Key words： Levosimendan Levocarnitine Refractory heart failure Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	BAI Qiao-yan
	LI Wei
	NI Chun-mei
	YANG Xiao-mei
	DONG Nan
	HAN Li-ying
	LI Yan-hui
	WANG Feng-gong

Cite this article:

BAI Qiao-yan,LI Wei,NI Chun-mei, et al. Effect observation of Levosimendan combined with Levocarnitine in the treatment of patients with refractory heart failure[J]. 中国当代医药, 2018, 25(1): 125-128.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I1/125

[1]	王雷，崔亮，魏嘉平，等.静脉注射左西孟旦治疗重度失代偿性心力衰竭患者的疗效分析[J].中华心血管病杂志，2015，38（6）：527-530.
[2]	张宇辉，卿恩明，张健，等.国产左西孟旦与多巴酚丁胺治疗急性失代偿性心力衰竭患者血液动力学和疗效对比观察[J].中华医学杂志，2015，92（8）：555-558.
[3]	Aissaoui N，Morshuis M，Paluszkiewicz L，et al.Comparison of biventricular and left ventricular assist devices for the management of severe right ventricular dysfunction in patients with end-stage heart failure[J].Asaio J，2014，60（4）：400-406.
[4]	栾晓嵘，李静，牛广红，等.左西孟旦治疗急性失代偿性心力衰竭患者不良反应的观察和护理[J].中华护理杂志，2015，47（4）：349-350.
[5]	Tsiouris A，Borgi J，Karam J，et al.Ischemic versus nonischemic dilated cardiomyopathy：The implications of heart failure etiology on left ventricular assist device outcomes[J].Asaio J，2015，59（2）：130-135.
[6]	栾晓嵘，李静，牛广红，等.左西孟旦治疗急性失代偿性心力衰竭患者的临床疗效及不良反应观察[J].中国实用护理杂志，2015，29（20）：38-41.
[7]	Rosenzweig EB，Brodie D，Abrams DC，et al.Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension[J].Asaio J，2014，60（1）：129-133.
[8]	何柳平，覃月秋，高艳，等.二维斑点追踪技术对左西孟旦治疗老年急性失代偿心力衰竭患者的疗效评价[J].山东医药，2017，57（17）：48-50.
[9]	马兰，金振一，金壹伍，等.左西孟旦对急性失代偿性心力衰竭患者心率变异性的影响[J].中国循环杂志，2014，29（3）：198-200.
[11]	傅炜钢.左西孟旦对老年急性失代偿性心力衰竭患者血流动力学的影响[J].中国老年学杂志，2014，34（19）：5376-5378.
[12]	占凡.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭的临床疗效[J].中国老年学杂志，2015，33（16）：3990-3991.
[10]	MadiasJE.ComparisonofleadaVR“netQRSarea”and“peakto-peak amplitude”as indices of all limb electrocardiogram leads：Implications for the diagnosis，management，and follow-up in patients with heart failure[J].Med Eng Phys，2015，34（8）：1037-1040.
[13]	魏群，刘勇，李焕明，等.左卡尼汀联合促红细胞生成素治疗慢性心力衰竭合并贫血患者的疗效[J].中国老年学杂志，2016，32（19）：4134-4135.
[14]	Rolle VL，Ojeda D，Hern M，et al.Embedding a Cardiac Pulsatile Model Into an Integrated Model of the Cardiovascular Regulation for Heart Failure Followup[J].Ieee Trans Biomed Eng，2016，58（10）：2982-2986.
[15]	González H，Infante O，Pérez-Grovas H，et al.Nonlinear dynamics of heart rate variability in response to orthostatism andhemodialysisinchronicrenalfailurepatients：Recurrence analysis approach[J].Med Eng Phys，2015，35（2）：178-187.
[16]	李芳学.左卡尼汀联合参麦注射液治疗缺血性心肌病心力衰竭 35 例效果观察[J].山东医药，2016，50（51）：59-60.
[17]	魏群，顾乃刚，刘勇，等.左卡尼汀注射液对扩张型心肌病重度心力衰竭病人C反应蛋白的影响[J].中国老年学杂志，2016，31（24）：4883-4884.
[18]	卢建敏，孙琳，吴彧，等.参麦注射液联合左卡尼汀治疗老年缺血性心肌病心力衰竭疗效观察[J].中国全科医学，2016，11（14）：1287-1288.
[19]	周慧敏.左卡尼汀对缺血性心力衰竭心室重构、心肌酶学及血脂代谢的影响[J].中国老年学杂志，2016，56（15）：4168-4169.
[20]	高鹏，寇广亚，武延海，等.左西孟旦治疗老年顽固性充血性心力衰竭并肾功能不全的疗效评价[J].实用医学杂志，2016，32（12）：2041-2045.